Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Obstetricia y Ginecología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib/+Paclitaxel vs Placebo+Paclitaxel as First-line Treatment for Patients With Locally Advanced (Inoperable) or Metastatic TNBC.
INTERVENTIONAL
Inicio: 25 de jun de 2019
ID: NCT03997123
Reclutando
ClinicalTrials.gov
Pilot Test for an Early Diagnosis Kit for Breast Cancer Based on Liquid Biopsies
OBSERVATIONAL
Inicio: 14 de jul de 2021
ID: NCT06439940
Completado
Fase 3
ClinicalTrials.gov
Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
INTERVENTIONAL
Inicio: 22 de nov de 2011
ID: NCT01419717
Completado
ClinicalTrials.gov
Mifepristone Treatment for Breast Cancer Patients Expressing Levels of Progesterone Receptor Isoform A (PRA) Higher Than Those of Isoform B (PRB): Neoadjuvant Therapy.
INTERVENTIONAL
Inicio: 1 de abr de 2016
ID: NCT02651844
Completado
Fase 2
ClinicalTrials.gov
A Three-arm, Randomized, Open Label, Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in the Treatment of Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole.
INTERVENTIONAL
Inicio: 26 de feb de 2013
ID: NCT01783444
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) in Combination With Paclitaxel Compared With Placebo With Paclitaxel for Patients With Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer
INTERVENTIONAL
Inicio: 25 de ago de 2017
ID: NCT03125902
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 23 de ene de 2012
ID: NCT01506609
Completado
Fase 3
ClinicalTrials.gov
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
INTERVENTIONAL
Inicio: 1 de dic de 2007
ID: NCT00528567
Desconocido
ClinicalTrials.gov
Effect of Ulipristal Acetate Administration on Serum Progesterone Levels and Glycodelin-A Endometrial Pattern in Women Undergoing Controlled Ovulation Stimulation.
INTERVENTIONAL
Inicio: 1 de jul de 2011
ID: NCT01391845
Completado
Fase 2
ClinicalTrials.gov
monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 23 de may de 2016
ID: NCT02675231
Terminado
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer
INTERVENTIONAL
Inicio: 2 de ago de 2018
ID: NCT03498716
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Double-blind, Placebo-controlled, Randomized Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Patients With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
INTERVENTIONAL
Inicio: 25 de nov de 2019
ID: NCT04177108
Terminado
Fase 2
ClinicalTrials.gov
An Open-Label, Phase II, Study to Evaluate Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer Receiving Treatment With Trastuzumab in Combination With Lapatinib or Chemotherapy (EGF117165)
INTERVENTIONAL
Inicio: 24 de oct de 2014
ID: NCT02213042
Activo, no recluta
Fase 3
ClinicalTrials.gov
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
INTERVENTIONAL
Inicio: 4 de oct de 2022
ID: NCT05514054
Completado
Fase 3
ClinicalTrials.gov
A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
INTERVENTIONAL
Inicio: 20 de sept de 2006
ID: NCT00337103
Completado
Fase 3
ClinicalTrials.gov
Phase 3 Randomized Study of TLK286 (Telcyta) Versus Doxil/Caelyx or Hycamtin as Third-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-1 (Assessment of Survival In Solid Tumors-1)]
INTERVENTIONAL
Inicio: 1 de jun de 2003
ID: NCT00057720
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations.
INTERVENTIONAL
Inicio: 6 de feb de 2015
ID: NCT02282020
Completado
ClinicalTrials.gov
Evaluation of an Emergency Obstetric and Neonatal Care (EmONC) Intervention Package to Reduce Adverse Pregnancy Outcomes in Low Resource Settings (The EmONC Trial)
INTERVENTIONAL
Inicio: 1 de dic de 2008
ID: NCT01073488
Reclutando
ClinicalTrials.gov
Long-term Risk of Recurrent Cervical Artery Dissection After Pregnancy (LONG-RECAP Study)
OBSERVATIONAL
Inicio: 1 de ene de 2023
ID: NCT06258109
Completado
Fase 3
ClinicalTrials.gov
Multicenter Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed By Docetaxel (AC-T) With Doxorubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab (Herceptin)(AC-TH) and With Docetaxel, Carboplatin and Trastuzumab (TCH) In The Adjuvant Treatment Of Node Positive and High Risk Node Negative Patients With Operable Breast Cancer Containing The HER2 Alteration
INTERVENTIONAL
Inicio: 1 de abr de 2001
ID: NCT00021255
Anterior
1
...
11
12
13
...
434
Siguiente
Filtros